Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Regeneron enters neurology field as FDA approves siRNA for myasthenia gravis

Regeneron’s siRNA therapy cemdisiran has become the second new drug approved by the FDA for myasthenia gravis inside of a week. Now named Livsayis, the therapy was approved by the FDA for ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Thursday 19 November →